INVO Fertility, Inc.
Close on Oct 19, 2026
- Market cap
- $1.56M
- P/E (TTM)
- –
- Dividend yield
- –
About INVO Fertility
Surgical & Medical Instruments & Apparatus, SIC 3841
The company is a healthcare and biotechnology enterprise that focuses on fertility services and therapeutics. Its core operational segments comprise fertility clinic services and therapeutics development. Through its clinic operations and product offerings, the organization provides reproductive healthcare treatments, fertility solutions, and related therapeutic innovations. It conducts operations and manages ventures linked to entities such as NAYA Therapeutics and fertility clinics, including the Wisconsin Fertility Institute. Its principal customers consist of individual fertility patients seeking reproductive care, clinical practitioners, and partner healthcare organizations requiring reproductive technologies and specialized therapeutic solutions.
Regarding geographic footprint and organizational scale, the text indicates operational interests and joint venture activities located in the United States, specifically within Georgia, Alabama, and Wisconsin through local joint ventures and clinic acquisitions. The provided text contains no details concerning the total number of medical facilities, retail locations, additional international countries of operation, or the exact location of the corporate headquarters.
Summary of the business section of INVO Fertility's latest annual report, written by StockData.
Company profile
Company
- Legal name
- INVO Fertility, Inc.
- Headquarters
- Sarasota, FL
- Address
- 5582 Broadcast Court 34240
- Phone
- (978) 878-9505
- Employees
- 14, Dec 31, 2025
- Industry
- Surgical & Medical Instruments & Apparatus
- Incorporated in
- Nevada
- Fiscal year ends
- December 31
- Auditor
- M&K CPAS, PLLC, The Woodlands, TX
Stock & identifiers
- Ticker
- IVF
- Exchange
- Nasdaq
- Shares outstanding
- 3M, Aug 14, 2026
- Public float
- $2.19M, Jun 30, 2025
- Filer category
- Non-accelerated filer<br>Smaller reporting company
- Stock splits
- 1-for-40 reverse, Jun 2, 2026; 1-for-5 reverse, Mar 27, 2026; 1-for-8 reverse, Nov 28, 2025; 1-for-3 reverse, Jul 21, 2025; 1-for-13 reverse, Apr 30, 2025; 1-for-12 reverse, Mar 18, 2025; 1-for-20 reverse, Aug 14, 2023; 1-for-20 reverse, Jul 28, 2023; 1-for-20 reverse, Aug 13, 2020
- SEC CIK
- 1417926
- CUSIP
- 44984F880
- ISIN
- US44984F8804
- EIN
- 20-4036208
Executives and directors
Officers and directors who filed ownership reports (Forms 3, 4, 5) in the last two years
| Name | Position | Shares owned |
|---|---|---|
| Steve Shum | Chief Executive Officer, Director | 674 |
| Terah Renee Krigsvold | Chief Financial Officer | 1 |
| Andrea Goren | Chief Financial Officer | 129,227 |
| Matthew K. Szot | Director | 0 |
| Trent D. Davis | Director | 49 |
| Barbara Ryan | Director | 46 |
| Rebecca Messina | Director | 33 |
CEO pay and shareholder return
Pay versus performance table from the proxy statement
| Fiscal year | CEO total pay | CEO pay actually paid | Other executives (avg) | Value of $100 invested | Peer group |
|---|---|---|---|---|---|
| FY2025 Steven Shum | $430.86K | $389.58K | $180.84K | $0 | – |
| FY2024 Steven Shum | $260.00K | $256.23K | $181.68K | $10 | – |
| FY2023 Steven Shum | $232.68K | $202.08K | $222.13K | $16 | – |
| FY2022 Steven Shum | $502.00K | $53.05K | $462.91K | $12 | – |
“Actually paid” adjusts reported pay for changes in the value of equity awards. Shareholder return assumes $100 invested at the start of the measurement period, as disclosed by the company.
Employees
Headcount reported in annual reports
“of December 31, 2025, INVO employed 14 full time employees.”
Corporate history
Events identified from SEC filings